State Key Laboratory of Natural and Biomimetic Drugs and Department of Natural Medicines, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
State Key Laboratory of Natural and Biomimetic Drugs and Department of Natural Medicines, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Phytomedicine. 2019 Jun;59:152775. doi: 10.1016/j.phymed.2018.11.035. Epub 2018 Nov 28.
Ginsenosides were considered as the main bioactive constituents in Ginseng Radix et Rhizoma (GRR). However, because of high polarity, ginsenosides were hard to be absorbed in human or animal gastrointestinal tract after oral administration. Up to now, very few studies have been performed in the area of simultaneous pharmacokinetic analysis of multiple ginsenosides with similar structures.
This research aimed to compare the different absorption characteristics of ginsenosides and aglycones between GRR and Baoyuan decoction (BYD), one of formulas containing GRR, with the same dosage.
GRR and BYD extracts were prepared with same method. A single dose of GRR and BYD extracts were administrated to rats through gavage, respectively. A solid phase extraction method was used to purify the plasma samples. An ultra-fast liquid chromatography coupled with tandem mass spectrometry (UFLC-MS/MS) method was established and fully validated for quantitative analysis. In addition, an in vitro incubation of GRR extract with intestinal flora was conducted to confirm the influence of gut microbiota to the absorption of ginsenosides and aglycones.
The results of incubation experiments showed that most high polar ginsenosides could transform to less polar ginsenosides via intestinal flora. The validated UFLC-MS/MS method was sensitive and precise to simultaneously analyze the pharmacokinetics of multiple ginsenosides. After oral administration of GRR and BYD extracts, the pharmacokinetic results showed that a total of 11 ginsenosides and 2 aglycones could be quantitatively determined in both groups of plasma. Besides, five compounds were only quantified in BYD extract group. In addition, another 21 ginsenosides could be qualitatively measured.
The results indicated significant pharmacokinetic differences of ginsenosides and aglycones between two groups. For most less polar ginsenosides who had better bioactivity, the preparation was possessed of higher plasma concentrations. The comparative results indicated that some co-existing compounds in BYD might inhibit the exocytosis of ginsenosides. Moreover, what is worth mentioning, some ginsenosides and aglycones could only be detected and quantified a few hours later after administration to rats. Combining with the in vitro incubation experiments, the results demonstrated that transformation of ginsenosides in gastrointestinal tract via intestinal flora existed during absorption.
人参皂苷被认为是人参根和根茎(GRR)中的主要生物活性成分。然而,由于其高极性,人参皂苷在口服后很难被人体或动物胃肠道吸收。到目前为止,很少有研究在同时分析具有相似结构的多种人参皂苷的药代动力学方面进行。
本研究旨在比较 GRR 和包含 GRR 的方剂保元汤(BYD)以相同剂量给药时,人参皂苷和苷元的不同吸收特征。
采用相同方法制备 GRR 和 BYD 提取物。分别通过灌胃给予大鼠单剂量的 GRR 和 BYD 提取物。采用固相萃取法纯化血浆样品。建立并充分验证了一种超快速液相色谱-串联质谱(UFLC-MS/MS)法进行定量分析。此外,还进行了 GRR 提取物与肠道菌群的体外孵育实验,以确认肠道菌群对人参皂苷和苷元吸收的影响。
孵育实验结果表明,大多数高极性人参皂苷可通过肠道菌群转化为极性较低的人参皂苷。验证后的 UFLC-MS/MS 方法灵敏、准确,可同时分析多种人参皂苷的药代动力学。口服 GRR 和 BYD 提取物后,药代动力学结果表明,两组血浆中均可定量测定 11 个人参皂苷和 2 个苷元。此外,BYD 提取物组还定量了 5 种化合物。此外,还定性测定了 21 种人参皂苷。
结果表明两组人参皂苷和苷元的药代动力学存在显著差异。对于大多数具有更好生物活性的极性较低的人参皂苷,其制剂具有更高的血浆浓度。比较结果表明,BYD 中的一些共存化合物可能会抑制人参皂苷的外排。此外,值得一提的是,一些人参皂苷和苷元在给大鼠给药后几个小时后才能被检测和定量。结合体外孵育实验结果表明,人参皂苷在胃肠道通过肠道菌群转化存在于吸收过程中。